| 28.52 0.44 (1.57%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.11 | 1-year : | 41 |
| Resists | First : | 30.05 | Second : | 35.11 |
| Pivot price | 26.62 |
|||
| Supports | First : | 24.83 |
Second : | 21.61 |
| MAs | MA(5) : | 28.27 |
MA(20) : | 25.7 |
| MA(100) : | 22.52 |
MA(250) : | 19.88 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 84.2  |
D(3) : | 85.6 |
| RSI | RSI(14): 64.8 |
|||
| 52-week | High : | 30.05 | Low : | 8.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMNM ] has closed below upper band by 21.2%. Bollinger Bands are 51% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 29.33 - 29.44 | 29.44 - 29.54 |
| Low: | 27.97 - 28.11 | 28.11 - 28.24 |
| Close: | 28.28 - 28.51 | 28.51 - 28.7 |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Sun, 23 Aug 2026
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - simplywall.st
Fri, 21 Aug 2026
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Thu, 20 Aug 2026
Immunome (IMNM) Institutional Ownership 2026 - MarketBeat
Wed, 19 Aug 2026
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Sun, 16 Aug 2026
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Fri, 14 Aug 2026
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 1.0831e+008 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 18,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2635e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 698.8 % |
| Return on Equity (ttm) | -29.8 % |
| Qtrly Rev. Growth | 4.01e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -23.66 |
| EBITDA (p.s.) | -8.6217e+007 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -197 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.21 |
| Price to Cash Flow | 11.62 |
| Dividend | 0 |
| Forward Dividend | 1.724e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|